UA104002C2 - МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa - Google Patents
МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIaInfo
- Publication number
- UA104002C2 UA104002C2 UAA201100191A UAA201100191A UA104002C2 UA 104002 C2 UA104002 C2 UA 104002C2 UA A201100191 A UAA201100191 A UA A201100191A UA A201100191 A UAA201100191 A UA A201100191A UA 104002 C2 UA104002 C2 UA 104002C2
- Authority
- UA
- Ukraine
- Prior art keywords
- heading
- inhibitors
- tafia
- normal
- sulfamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Данное изобретение касается соединений формулы (I), которые являются ингибиторами ингибитора фибринолиза, активированного активированным тромбином.Соединения формулы (I) пригодны для получения лекарственных средств для профилактики, вторичной профилактики и лечения одного или более нарушений, связанных с тромбозами, эмболиями, гиперкоагулированостью или фиброзными изменениями.(I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290520 | 2008-06-06 | ||
PCT/EP2009/003650 WO2009146802A1 (de) | 2008-06-06 | 2009-05-22 | Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia |
Publications (1)
Publication Number | Publication Date |
---|---|
UA104002C2 true UA104002C2 (ru) | 2013-12-25 |
Family
ID=39800716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201100191A UA104002C2 (ru) | 2008-06-06 | 2009-05-22 | МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa |
Country Status (35)
Country | Link |
---|---|
US (5) | US8580777B2 (ru) |
EP (1) | EP2300462B1 (ru) |
JP (1) | JP5531011B2 (ru) |
KR (1) | KR101673886B1 (ru) |
CN (1) | CN102056922B (ru) |
AR (1) | AR072007A1 (ru) |
AU (1) | AU2009254257B2 (ru) |
BR (1) | BRPI0913349A2 (ru) |
CA (1) | CA2726554C (ru) |
CL (1) | CL2009001358A1 (ru) |
CO (1) | CO6321271A2 (ru) |
CR (1) | CR11807A (ru) |
CY (1) | CY1115604T1 (ru) |
DK (1) | DK2300462T3 (ru) |
DO (1) | DOP2010000363A (ru) |
EC (1) | ECSP10010655A (ru) |
ES (1) | ES2494390T3 (ru) |
HK (1) | HK1152936A1 (ru) |
HN (1) | HN2010002558A (ru) |
HR (1) | HRP20140787T1 (ru) |
IL (1) | IL209772A (ru) |
MA (1) | MA32322B1 (ru) |
MX (1) | MX2010012793A (ru) |
NI (1) | NI201000203A (ru) |
NZ (1) | NZ589671A (ru) |
PL (1) | PL2300462T3 (ru) |
PT (1) | PT2300462E (ru) |
RU (1) | RU2502736C2 (ru) |
SI (1) | SI2300462T1 (ru) |
SV (1) | SV2010003747A (ru) |
TW (1) | TWI455928B (ru) |
UA (1) | UA104002C2 (ru) |
UY (1) | UY31868A (ru) |
WO (1) | WO2009146802A1 (ru) |
ZA (1) | ZA201007719B (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5531011B2 (ja) | 2008-06-06 | 2014-06-25 | サノフイ | TAFIaの阻害剤としての大環状尿素およびスルファミド誘導体 |
UY31923A (es) | 2008-06-23 | 2010-01-29 | Astrazeneca Ab | Nuevos heterociclos para su uso como inhibidores de trombina |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
DK2822953T5 (en) * | 2012-03-06 | 2017-09-11 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
MX2015016961A (es) * | 2013-06-10 | 2016-04-25 | Sanofi Sa | Derivados de urea macrociclicos como inhibidores de tafia, su preparacion y su uso como productos farmaceuticos. |
UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
CN103755852B (zh) * | 2013-12-18 | 2015-12-09 | 湖北大学 | 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途 |
CN106631832A (zh) * | 2016-10-08 | 2017-05-10 | 帕潘纳(北京)科技有限公司 | 一种氨基醚类化合物的制备方法 |
US10411291B2 (en) * | 2017-03-22 | 2019-09-10 | Nanotek Instruments, Inc. | Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU667995B2 (en) | 1993-02-15 | 1996-04-18 | Bayer Aktiengesellschaft | New pseudopeptides having an antiviral action |
TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
US5888971A (en) | 1996-02-20 | 1999-03-30 | Ortho Pharmaceutical Corporation, Inc. | Macrocyclic peptides useful in the treatment of thrombin related disorders |
WO1999011606A2 (en) | 1997-08-28 | 1999-03-11 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
US6124278A (en) * | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
US6482921B1 (en) | 1999-01-28 | 2002-11-19 | Essential Therapeutics, Inc. | Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use |
DE60042585D1 (de) * | 2000-02-29 | 2009-09-03 | Univ Firenze | 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken |
DE102004020186A1 (de) * | 2004-04-22 | 2005-11-17 | Aventis Pharma Deutschland Gmbh | Heterocyclylessigsäuren als Inhibitoren von TAFla |
ES2537093T3 (es) | 2006-12-06 | 2015-06-02 | Sanofi | Derivados de sulfamida utilizados como inhibidores de TAFIa |
JP5531011B2 (ja) | 2008-06-06 | 2014-06-25 | サノフイ | TAFIaの阻害剤としての大環状尿素およびスルファミド誘導体 |
-
2009
- 2009-05-22 JP JP2011512000A patent/JP5531011B2/ja not_active Expired - Fee Related
- 2009-05-22 DK DK09757185T patent/DK2300462T3/da active
- 2009-05-22 EP EP09757185.5A patent/EP2300462B1/de active Active
- 2009-05-22 NZ NZ589671A patent/NZ589671A/en not_active IP Right Cessation
- 2009-05-22 WO PCT/EP2009/003650 patent/WO2009146802A1/de active Application Filing
- 2009-05-22 MX MX2010012793A patent/MX2010012793A/es active IP Right Grant
- 2009-05-22 PT PT09757185T patent/PT2300462E/pt unknown
- 2009-05-22 SI SI200931001T patent/SI2300462T1/sl unknown
- 2009-05-22 CA CA 2726554 patent/CA2726554C/en not_active Expired - Fee Related
- 2009-05-22 PL PL09757185T patent/PL2300462T3/pl unknown
- 2009-05-22 CN CN2009801210767A patent/CN102056922B/zh not_active Expired - Fee Related
- 2009-05-22 ES ES09757185.5T patent/ES2494390T3/es active Active
- 2009-05-22 RU RU2010154089/04A patent/RU2502736C2/ru not_active IP Right Cessation
- 2009-05-22 BR BRPI0913349A patent/BRPI0913349A2/pt not_active Application Discontinuation
- 2009-05-22 AU AU2009254257A patent/AU2009254257B2/en not_active Ceased
- 2009-05-22 UA UAA201100191A patent/UA104002C2/ru unknown
- 2009-05-22 US US12/996,460 patent/US8580777B2/en not_active Expired - Fee Related
- 2009-05-22 KR KR1020107027133A patent/KR101673886B1/ko active IP Right Grant
- 2009-06-04 AR ARP090102005 patent/AR072007A1/es unknown
- 2009-06-04 TW TW98118477A patent/TWI455928B/zh not_active IP Right Cessation
- 2009-06-04 CL CL2009001358A patent/CL2009001358A1/es unknown
- 2009-06-04 UY UY31868A patent/UY31868A/es not_active Application Discontinuation
-
2010
- 2010-10-28 ZA ZA2010/07719A patent/ZA201007719B/en unknown
- 2010-11-22 NI NI201000203A patent/NI201000203A/es unknown
- 2010-11-23 DO DO2010000363A patent/DOP2010000363A/es unknown
- 2010-11-23 CR CR11807A patent/CR11807A/es not_active Application Discontinuation
- 2010-11-30 MA MA33377A patent/MA32322B1/fr unknown
- 2010-12-01 CO CO10151420A patent/CO6321271A2/es active IP Right Grant
- 2010-12-02 SV SV2010003747A patent/SV2010003747A/es unknown
- 2010-12-02 EC ECSP10010655 patent/ECSP10010655A/es unknown
- 2010-12-03 HN HN2010002558A patent/HN2010002558A/es unknown
- 2010-12-05 IL IL209772A patent/IL209772A/en not_active IP Right Cessation
-
2011
- 2011-07-07 HK HK11107008A patent/HK1152936A1/xx not_active IP Right Cessation
-
2013
- 2013-10-08 US US14/048,339 patent/US8722655B2/en not_active Expired - Fee Related
-
2014
- 2014-03-26 US US14/226,132 patent/US9126955B2/en not_active Expired - Fee Related
- 2014-08-08 CY CY20141100631T patent/CY1115604T1/el unknown
- 2014-08-20 HR HRP20140787AT patent/HRP20140787T1/hr unknown
-
2015
- 2015-07-28 US US14/811,364 patent/US9309207B2/en not_active Expired - Fee Related
-
2016
- 2016-03-01 US US15/057,920 patent/US9688645B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA104002C2 (ru) | МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa | |
MY140903A (en) | Imidazole derivatives used as tafia inhibitors | |
EP2595482A4 (en) | ALDOSTERONSYNTHASEHEMMER | |
SG179034A1 (en) | 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes | |
MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
GEP20146169B (en) | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
MY151246A (en) | Benzofuranyl derivatives | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
MX2009010960A (es) | Compuestos heterociclicos y sus metodos de uso. | |
MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
MA33894B1 (fr) | Procedes d'administration therapeutique de la pirferidone | |
TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
MX340756B (es) | Compuestos de quinazolina como inhibidores de serina/treonina quinasa. | |
MX2013005118A (es) | Inhibidores selectivos de glucosidasas y sus usos. | |
GB2466912A (en) | Compositions and methods for treating lysosomal disorders | |
WO2016176279A8 (en) | Uses of cannabidiol for treatment of infantile spasms | |
EP2012780A4 (en) | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES AS POTENTE PARP HEMMER | |
WO2009131654A3 (en) | Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives | |
MX2009005516A (es) | Derivados de urea y de sulfamida en calidad de inhibidores de tafia. | |
WO2007115805A3 (en) | Aurora kinase inhibitors | |
CA2887539C (en) | Azaquinazoline carboxamide derivatives | |
MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
WO2010062506A3 (en) | Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors |